A Scoring Method for Immunohistochemical Staining on Ki67
A Scoring Method for Immunohistochemical Staining on Ki67
Guo, Rui; Ma, Li; Bai, Xiomei; Miao, Li; Li, Zongfang; Yang, Jun
2021-03-13 00:00:00
An accurate interpretation of immunohistochemistry (IHC) staining results is crucial for precise disease diagnosis. In this study, we present a novel scoring method for interpreting and reporting of IHC staining assay results for the nuclear-type molecule. On the basis of the histologic characteristics, the samples were subdivided into 3 basic structural units and tissue subtypes including covered, mosaic, and mesenchymal subtypes. A cut-off of moderate-positive (2+) cells and 10% as the differential expression were applied to stratify the results into 11 grade scoring system (0 to X level). The observer can directly identify and count the number and percentage of positive cells from IHC staining data. Furthermore, Ki67 staining results in 88 carcinoma specimens were re-evaluated to determine the ease, reliability, reproducibility, and variance among different observers. The results indicated the consistency ratio of 68.0% for the mosaic subtype and 80% for the mesenchymal subtype, and 68.2% for the covered subtype by 5 experienced pathologists independently. Using 10% as the cut-off threshold, the consistency ratio of 92.5%, 96.8%, and 92.9% was noted for mosaic, mesenchymal, and covered subtypes, respectively. Besides, the correlation of counts revealed excellent agreement among the 5 independent pathologists. Overall, the proposed IHC scoring method is a novel, simple, reliable, and reproducible grading system for accurate interpretation of IHC staining data. Furthermore, the presented practical grading approach has the potential to improve the clinical evaluation of the IHC staining data for personalized therapy.
http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.pngApplied Immunohistochemistry & Molecular MorphologyWolters Kluwer Healthhttp://www.deepdyve.com/lp/wolters-kluwer-health/a-scoring-method-for-immunohistochemical-staining-on-ki67-0AIkMEoKFS
A Scoring Method for Immunohistochemical Staining on Ki67
An accurate interpretation of immunohistochemistry (IHC) staining results is crucial for precise disease diagnosis. In this study, we present a novel scoring method for interpreting and reporting of IHC staining assay results for the nuclear-type molecule. On the basis of the histologic characteristics, the samples were subdivided into 3 basic structural units and tissue subtypes including covered, mosaic, and mesenchymal subtypes. A cut-off of moderate-positive (2+) cells and 10% as the differential expression were applied to stratify the results into 11 grade scoring system (0 to X level). The observer can directly identify and count the number and percentage of positive cells from IHC staining data. Furthermore, Ki67 staining results in 88 carcinoma specimens were re-evaluated to determine the ease, reliability, reproducibility, and variance among different observers. The results indicated the consistency ratio of 68.0% for the mosaic subtype and 80% for the mesenchymal subtype, and 68.2% for the covered subtype by 5 experienced pathologists independently. Using 10% as the cut-off threshold, the consistency ratio of 92.5%, 96.8%, and 92.9% was noted for mosaic, mesenchymal, and covered subtypes, respectively. Besides, the correlation of counts revealed excellent agreement among the 5 independent pathologists. Overall, the proposed IHC scoring method is a novel, simple, reliable, and reproducible grading system for accurate interpretation of IHC staining data. Furthermore, the presented practical grading approach has the potential to improve the clinical evaluation of the IHC staining data for personalized therapy.
Journal
Applied Immunohistochemistry & Molecular Morphology
– Wolters Kluwer Health
Published: Mar 13, 2021
Recommended Articles
Loading...
References
Review of recent molecular landscape knowledge of gastric cancer
NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies
Biomarker tests for molecularly targeted therapies—the key to unlocking precision medicine
Predictive biomarkers and companion diagnostics. The future of immunohistochemistry: “in situ proteomics,” or just a “stain”?
Integrating predictive biomarkers and classifiers into oncology clinical development programmes
American Society of Clinical Oncology/College of American Pathologists guidelines should be scientifically validated
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
Quality management in immunohistochemistry
Controls for immunocytochemistry: an update
Image analysis of immunohistochemistry is superior to visual scoring as shown for patient outcome of esophageal adenocarcinoma
Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer
Base-rate error in the interpretation of immunohistochemistry
Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer
Ki67 as a biomarker of prognosis and prediction: is it ready for use in routine pathology practice?
Immunocytochemical methods and protocols
MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups
Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry
Immunological properties of an antibody containing a fluorescent group
Technical aspects of immunohistochemistry
Rabbit monoclonal antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies
Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors
Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue
Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment II
Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer
Internal quality control on HER2 status determination in breast cancers: experience of a cancer center
An international study to increase concordance in Ki67 scoring
The relation between percentage of immunostained cells and amplification status in breast cancers with equivocal result for HER2 immunohistochemistry
Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value
Recommendations for improved standardization of immunohistochemistry
Share the Full Text of this Article with up to 5 Colleagues for FREE
Sign up for your 14-Day Free Trial Now!
Read and print from thousands of top scholarly journals.
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
